Merck KGaA to Acquire Silence Therapeutics for $20.00/ADS in $1.3B All-Cash Deal

summarizeSummary

Silence Therapeutics agreed to be acquired by Merck KGaA for $20.00 per ADS in cash, valuing the equity at about $1.3 billion — a 130% premium to the pre-announcement close. Shareholder and court approvals are required, and the deal is expected to close in Q1 2027.

check_boxKey Events · M&A and Partnerships · SLN

• Merck KGaA Agrees to Buy Silence

  All-cash scheme of arrangement at $20.00 per ADS ($6.6667 per ordinary share), implying an equity value of roughly $1.3 billion and an enterprise value of $1.1 billion.

• 130% Premium to Pre-Deal Close

  The $20.00 per ADS price is a 130% premium to the $8.70 close on October 16, 2026 and an 82% premium to the 30-day VWAP of $10.99.

• Approvals and Closing Timeline

  The deal requires 75%-in-value shareholder approval at the Scheme Meeting and Company GM, sanction by the High Court of England and Wales, and HSR plus German antitrust clearance. Closing is expected in Q1 2027, with an April 30, 2027 outside date.

• 14% of Votes Already Locked Up

  Certain securityholders holding approximately 14% of Silence's voting power signed voting and support agreements to vote in favor of the transaction.

auto_awesomeAnalysis · SLN · Life Sciences

Silence is being bought outright at $20.00 per ADS in cash — a 130% premium to the $8.70 close on October 16 and 82% above the 30-day VWAP of $10.99. That price now anchors the stock; the open question is deal completion, not standalone valuation. Closing is targeted for Q1 2027 and hinges on a 75%-in-value shareholder vote, High Court sanction and antitrust clearance (HSR plus German approval). No financing condition applies, and holders of roughly 14% of the voting power have already agreed to vote in favor. A $13 million break fee applies if the board switches to a superior proposal.